To monitor therapeutic response by treatment of isotype (ISO) and trastuzumab (TRA) using the evaluation of HER2 expression level with 89Zr-DFO-pertuzumab, immuno-PET imaging was performed in the JIMT-1 breast cancer xenograft model. Here, ERBB2 is linked to breast carcinoma.